
Medicare Renal Dialysis Facility Manual (Non-Hospital Operated)

Department of Health and
Human Services (DHHS)
HEALTH CARE FINANCING
ADMINISTRATION (HCFA)

Transmittal 92

Date: JUNE 1, 2001

REFER TO CHANGE REQUEST 1682

<u>HEADER SECTION NUMBERS</u>	<u>PAGES TO INSERT</u>	<u>PAGES TO DELETE</u>
Table of Contents, Chapter 3	3-1 – 3-2 (2 pp.)	3-1 – 3-2 (2 pp.)
319.4 – 319.4 (Cont.)	3-15.18 – 3-15.19 (2 pp.)	3-15.18 – 3-15.19 (2 pp.)

NEW/REVISED MATERIAL--EFFECTIVE DATE: October 1, 2001

Section 319.4, Billing for Intravenous Iron Therapy, adds a new section providing coverage, billing and payment instructions for iron sucrose injection as a first line treatment of iron deficiency anemia when furnished intravenously to patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy.

Until a more specific HCPCS code is assigned, use J3490 to bill for iron sucrose injection.

This section is revised to correct how payment is made for HCPCS J3490 (Unclassified drug). This section is also revised to delete bill type 82X as an applicable bill type, correct the revenue code reporting and change the HCPCS reporting for sodium ferric gluconate complex in sucrose injection.

DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted.

ESRD
BILLING PROCEDURES

Section

Identifying Medicare Beneficiaries

Health Insurance Card and Other Evidence of Medicare Entitlement	300
Identifying Health Insurance (HI) Claim Numbers	304
HICNs Assigned by the Railroad Retirement Board	304.1
All-Inclusive List of Potentially Valid RRB HICN.....	304.2
Change in Health Insurance Claim Numbers	304.3
Reduction in Payment Due to P.L. 99-177	305
Part B Deductible.....	306
Part B Coinsurance	308
Determining How Much to Charge Patient Before Billing is Submitted for Part B Payment.....	310

Beneficiary Request for Payment

Filing a Request for Payment	312
Request for Payment on Facility Record	312.2
Time Limitation of Filing Claims for Dialysis Services	312.3
Execution of the Request for Payment	314
Scope of Waiver of Liability Provision	315
Form HCFA-1483, Provider Billing for Medical and Other Health Services	317
General Information Concerning the Composite Rate.....	317.1
Beneficiary Selection, Form HCFA-382, for Home Dialysis Patients	318
Epoetin(EPO).....	319
Payment for Drugs	319.1
Blood and Blood Services Furnished in Independent Dialysis Facilities	319.2
Coding for Adequacy of Hemodialysis.....	319.3
Billing for Intravenous Iron Therapy.....	319.4

Uniform Billing

Completion of Form HCFA-1450 by Independent Facilities for Home Dialysis	
Items and Services Billed Under the Composite Rate (Method I.).....	320
Submitting Corrected Bills.....	320.1
Completion of Form HCFA-1450, by Independent Facilities for Support	
Services for Method II Beneficiaries	321
Clinical Laboratory Improvement Amendments (CLIA)	322

ESRD
BILLING PROCEDURES

	<u>Section</u>
Billing in Situations Where Medicare is <u>Secondary Payer</u>	
Bill Preparation Where Medicare Benefits are Secondary to Employer Group Health Plans When Individuals are Entitled To Benefits Solely on the Basis of ESRD	323
Frequency of Billing.....	323.1

Refunds

Refund of Monies Incorrectly Collected	324
Return or Other Disposition of Monies Incorrectly Collected	324.1
Appropriate Time Limits Within Which Facility Must Dispose of Sums Incorrectly Collected.....	324.2
Former Facility	324.3
Credit Balance Reporting Requirements	325
Submitting the HCFA-838.....	325.1
Completing the HCFA-838.....	325.2
Payment of Amount Owed Medicare	325.3
Records Supporting HCFA-838 Data	325.4
Provider-Based Home Health Agencies	325.5
Compliance with MSP Regulations	325.7
Exhibit I Medicare Credit Balance Report Certification.....	
Exhibit II Medicare Credit Balance Report (HCFA-838).....	

Protests and Appeals

Facility Protests of Payment Determination.....	326
Beneficiary Appeals (Part B)	328
Reopening and Revision of Medicare Claims Decision.....	330

Retention of Records

Retention of Health Insurance Records	332
Destruction of Health Insurance Records	332.1

Claims Processing Timeliness Requirements

Claims Processing Timeliness	333
Pneumococcal Pneumonia, Influenza Virus and Hepatitis B Vaccines.....	334
Exhibits	399

If these codes are sufficient to describe the services provided by blood banks in your area, use the codes in billing. However, if these codes do not describe the services you are billing for, ask your intermediary to furnish the appropriate codes.

For supplies, use revenue code 270. Your intermediary establishes local codes for blood administration sets and filters and determines reasonable charge amounts for you.

319.3 Coding for Adequacy of Hemodialysis.--

A. General.--All hemodialysis claims must indicate the most recent Urea Reduction Ratio (URR) for the dialysis patient. Code all claims using HCPCS code 90999 along with the appropriate G modifier listed in section B.

B. Billing Requirements.--Claims for dialysis treatments must include the adequacy of dialysis data as measured by URR. Dialysis facilities must monitor the adequacy of dialysis treatments monthly for facility patients. Home hemodialysis and peritoneal dialysis patients may be monitored less frequently, but not less than quarterly.

HCPCS code 90999 (unlisted dialysis procedure, inpatient or outpatient) must be reported in field location 44 for all bill types 72X. Attach the appropriate G-modifier in field location 44 (HCPCS/RATES), for patients that received seven or more dialysis treatments in a month. Continue to report revenue codes 820, 821, 825, and 829 in field location 43.

- G1 Most recent URR of less than 60%
- G2 Most recent URR of 60% to 64.9%
- G3 Most recent URR of 65% to 69.9%
- G4 Most recent URR of 70% to 74.9%
- G5 Most recent URR of 75% or greater

For patients that have received dialysis 6 days or less in a month, use the following modifier:

- G6 ESRD patient for whom less than seven dialysis sessions have been provided in a month.

The techniques to be used to draw the pre- and post-dialysis blood urea Nitrogen samples are listed in the National Kidney Foundation Dialysis Outcomes Quality Initiative Clinical Practice Guidelines for Hemodialysis Adequacy, Guideline 8, Acceptable Methods for BUN sampling, New York, National Kidney Foundation, 1997, pp. 53 - 60.

319.4 Billing for Intravenous Iron Therapy.--

A. General.--Iron deficiency is a common condition in end stage renal disease (ESRD) patients undergoing hemodialysis. Iron is a critical structural component of hemoglobin, a key protein found in normal red blood cells (RBCs) which transports oxygen. Without this important building block, anemic patients experience difficulty in restoring adequate, healthy RBC (hematocrit) levels. Clinical management of iron deficiency involves treating patients with iron replacement products while they undergo hemodialysis.

B. Billing Requirements.--For claims with dates of service on or after December 1, 2000, sodium ferric gluconate complex in sucrose injection is covered by Medicare for first line treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy. **Payment is made on a reasonable cost basis for claims with dates of service on or after December 1, 2000. Payment is made pursuant to 42 CFR 405.517 for claims with dates of service on or after January 1, 2001.**

For claims with dates of service on or after October 1, 2001, Medicare also covers iron sucrose injection as a first line treatment of iron deficiency anemia when furnished intravenously to patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy. Payment is made on a reasonable cost basis. Deductible and coinsurance apply.

Bill on Form HCFA-1450 or electronic equivalent.

C. Applicable Bill Types.--The appropriate bill types are 13X, 72X, and 85X.

When utilizing the UB-92 flat file use record type 40 to report bill type. Record type (Field No. 1), sequence number (Field No. 2), patient control number (Field No. 3), and type of bill (Field No. 4) are required. When utilizing the hard copy UB-92 (Form-1450) report the applicable bill type in Form Locator (FL) 4 "Type of Bill." When utilizing the Medicare A 837 Health Care Claim version 3051 implementations 3A.01 and 1A.C1, report the applicable bill type in 2-130-CLM01, CLM05-01, and CLM05-03.

D. Revenue Code Reporting.--Report revenue code 636. When utilizing the UB-92 flat file use record type 61, Revenue Code (Field No. 5). When utilizing the hard copy UB-92, report the revenue code in FL 42 "Revenue Code." When utilizing the Medicare A 837 Health Care Claim version 3051 implementations 3A.01 and 1A.C1, report the applicable revenue code in 2-395-SV201.

E. HCPCS Reporting.—For claims with dates of service on or after December 1, 2000, report HCPCS code J3490 (Unclassified drugs) for sodium ferric gluconate complex in sucrose injection. For claims with dates of service on or after January 1, 2001, report HCPCS code J2915 for sodium ferric gluconate complex in sucrose injection. Until a specific code is developed for iron sucrose injection, report HCPCS code J3490 (Unclassified drugs). When utilizing the UB-92 flat file use record type 61, HCPCS code (Field No. 6) to report HCPCS code. When utilizing the hard copy UB-92 report the HCPCS code in FL 44 "HCPCS/Rates." When utilizing the Medicare A 837 Health Care Claim version 3041 implementations 3A.01 and 1A.C1, report the HCPCS/CPT in 2-395-SV202-02.